Engaging cancer patients in genomic testing decisions
Official title: Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
Run by Washington University School of Medicine · NCT06340646 · Data updated 2026-11-12
This study is testing if letting cancer patients choose what genetic information they want to receive helps them feel more informed and satisfied with their health decisions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 990 (estimated) |
| Sponsor | Washington University School of Medicine Academic / other |
| Locations | 1 site (St Louis, Missouri) |
| Status | Recruiting |
| Started | October 18, 2022 |
| Main results expected | January 31, 2027 |
| Study ends | January 31, 2027 |
| Registry record updated | July 14, 2026 |
| Trial ID | NCT06340646 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include African-American patients diagnosed with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer who are at least 18 years old.
✕Probably not a fit
Patients outside the specified demographics or those with other types of cancer may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The WU-PE-CGS project aims to enhance the involvement of cancer patients and survivors in research by allowing them to choose the types of genomic results they wish to receive. This study focuses on patients with cholangiocarcinoma, multiple myeloma, and early onset colon or rectal cancer, particularly among African-American individuals. The Engagement Optimization Unit will assess how this direct engagement influences participants' knowledge, expectations, personal utility, and decision-making conflicts regarding their health. By building a scientific evidence base, the study seeks to improve patient satisfaction and health outcomes.
Why it matters
Potential benefit: If successful, this approach could empower patients with cancer to make informed decisions about their genomic information, potentially improving their health outcomes and satisfaction.
How similar studies have gone: While the engagement of patients in genomic testing is a growing area of interest, this specific approach is novel and has not been extensively tested in similar studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Eligibility Criteria: * Patients with cholangiocarcinoma, multiple myeloma, or early onset colon or rectal cancer. * If diagnosed with multiple myeloma, must be African-American. * If diagnosed with colon or rectal cancer, must be African-American AND must be no older than 65 years old at the time of diagnosis. * At least 18 years old * Able to understand and willing to sign an IRB-approved written informed consent document
Where it's running
-
Washington University School of Medicine
St Louis, Missouri, United States Recruiting
Study contacts
- Principal investigator: Graham Colditz, M.D., DrPH, MPH — Washington University School of Medicine
- Study coordinator: Graham Colditz, M.D., DrPH, MPH
- Email: colditzg@wustl.edu
- Phone: 314-454-7939
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Testing MDX2001 for advanced solid tumors
This study is testing a new drug called MDX2001 to see if it can safely help people with advanced solid tumors like breast or colon cancer.
-
Treatment using CEA-targeted CAR-T cells for advanced solid tumors
This study is testing a new type of immune therapy using CAR-T cells to see if it can help people with advanced solid tumors that have a specific marker called CEA.
-
A resource for collecting cancer data and biospecimens
This study is creating a resource to collect health information and samples from cancer patients and healthy individuals to help improve cancer prevention and treatment strategies.
-
DEM301 in advanced colorectal cancer: a first-in-human test
This first-in-human Phase 1 study tests DEM301 in adults with advanced metastatic colorectal cancer to see if it is safe, how it behaves in the body, and whether it shows any signs of activity.
-
Quality of life after colorectal cancer treatment
This project will test whether late side effects at 6, 12, and 24 months affect quality of life in people aged 25–65 who completed initial treatment for colorectal cancer at the Institute of Oncology Ljubljana.
-
CEA-targeted CAR-T for advanced CEA-positive solid tumors
This trial will try CEA-targeted CAR-T cell infusions in adults with advanced CEA-positive cancers (such as colorectal, gastric, esophageal, lung, or pancreatic cancer) to see if the treatment is safe and helps control the disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.